• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • ICH E8 (R1) General Considerations for Clinical Studies have been approved in China

ICH E8 (R1) General Considerations for Clinical Studies have been approved in China

ICH E8 (R1)
Wednesday, 07 September 2022 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

ICH E8 (R1) General Considerations for Clinical Studies have been approved in China

ICH E8 (R1) General Considerations for Clinical Studies and E14 Clinical Evaluation of QT/QTc Interval Prolongation and Potential Proarrhythmic Effects of Non-antiarrhythmic Drugs will come into effect in July 2023.

On August 12, 2022, the National Medical Products Administration (NMPA) published announcement (No. 61 of 2022) about its decision to apply the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines on E8 (R1) General Considerations for Clinical Studies and E14 Clinical Evaluation of QT/QTc Interval Prolongation and Potential Proarrhythmic Effects of Non-antiarrhythmic Drugs.

The requirements are as follows:

  1. From July 31, 2023, the requirements for the initiation of clinical drug according to E8(R1) shall apply. This will mean that from the date of implementation version E8: General Considerations for Clinical Studies shall cease to apply.
  2. From July 31, 2023, the relevant requirements for the initiation of clinical drug research according to ICH E14 shall apply. ICH E14 was implemented by ICH on May 12, 2005.

Highlights

  • Compared with ICH E8 first published by the ICH on July 17, 1997, E8 (R1) General Considerations for Clinical Studies has undergone major framework and content revisions
  • ICH E8(R1) is the first reform step towards the comprehensive revision of ICH E6 Good Clinical Practice initiated by the ICH in 2017. The new version of E8 takes the realization of the latest concept of “fit for purpose” data quality as one of the basic considerations for all clinical research. It also clearly adopts the Quality by Design (QbD) concept to drive the quality of clinical research, in order to improve efficiency and success rate. Combined with the updated content, it can be expected that the quality management concept in the field of clinical research will mean that quality must be part of the design of a clinical trial.
  • ICH E14 Clinical Evaluation of QT/QTc Interval Prolongation and Potential Proarrhythmic Effects of Non-Antiarrhythmic Drugs is the first ICH guideline to be applied in China. The guidelines provide advice on the design, conduct, analysis, and interpretation of clinical studies to help evaluate the potential role of drugs in delaying cardiac repolarization.
  • It is worth mentioning that on July 9, 2022, China´s Center for Drug Evaluation (CDE) issued a notice to publicly solicit domestic stakeholder opinions on ICH guideline M12: Drug Interactions which is required to be released in September 2022. Feedback via email (lil@cde.org.cn; fushj@cde.org.cn) before September 30. Once the ICH member states agree on the revision of this guideline, they will implement ICH M12 successively. Drug applicants should follow this guidance in anticipation (see Internal links) to guide drug development and understand regulatory requirements.

By Sophie. If you would like to learn more about or our registration and CRO services for pharmaceuticals, medical devices, IVDs, cosmetics, health foods, industrial or consumer goods contact Cisema.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers
📣 Sign up for our newsletter

What you can read next

Clinical Trials GMP management
Clinical Trials GMP Management Specification for Drugs – Appendix (Draft) Issued
Measures for the supervision and administration of drug production
Measures for the Supervision and Administration of Drug Production in China – A Recap
Changes Regarding the Approval of “Non-Special” Cosmetics

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.